Serum Triamcinolone Levels Following Interlaminar Epidural Injection

Area of Science:

• Pharmacology
• Pain Medicine
• Endocrinology

Background:

• Lumbar interlaminar epidural steroid injections (ESIs) are common pain management procedures.
• Limited data exists on serum steroid levels post-epidural administration.
• This study investigates triamcinolone acetonide pharmacokinetics following lumbar ESI.

Purpose of the Study:

• To determine the pharmacokinetics of fluoroscopically guided, epidural-administered triamcinolone acetonide.
• To analyze serum steroid levels in patients with chronic low-back pain receiving ESIs.
• To explore potential associations between serum levels and adverse endocrine effects.

Main Methods:

• A cohort of 10 patients receiving lumbar interlaminar ESIs (L4-L5 or L5-S1) was studied.
• Blood samples were collected serially for 42 days post-injection.
• Serum triamcinolone concentrations were quantified using tandem mass spectrometry.

Main Results:

• The terminal elimination half-life of epidural triamcinolone was determined to be 523 hours.
• Peak serum triamcinolone concentrations reached 4.1 ng/mL within 24 hours post-administration.
• Noncompartmental analysis provided pharmacokinetic insights.

Conclusions:

• The observed pharmacokinetics of epidural triamcinolone align with known adverse endocrine effects.
• Further research is needed to determine pharmacokinetics of other epidural steroids.
• Clinical trials should incorporate serum level analysis to investigate links to outcomes and endocrine effects.